Influx Healthtech reported robust H1 FY26 earnings.

Revenue from Operations grew 39% YoY to 66.8 Cr.

EBIDTA surged 61% YoY to 14.7 Cr, expanding margins to 22.0%, while PAT increased 78% YoY to 10.0 Cr, reaching a 15.0% margin.

Nutraceuticals remain the dominant segment, contributing 90% of revenue.

The company recently commercialized a new multi-line production facility, significantly boosting capacity for tablets, liquids, sachets, and capsules.

Management plans to utilize IPO funds to further expand capacity by 2.5x, specifically for automated beverage and high-capacity pet food lines.

The aim is to more than double the business by FY27 with similar margins, supported by continuous product portfolio expansion and strong in-house R&D. Operational efficiency improved, with debtor days dropping to 100.